Why is regulatory harmonization such a big topic? How have manufacturing challenges changed over the years? How has the COVID-19 pandemic affected the field? What are the biggest prospects for growth in the CGT space? How has investment changed in CGT over the years? We met with Phil Vanek, CTO at Gamma Biosciences and Industrial Committee Member and Business Development and Finance Committee Member at ISCT, to ask these questions and more. Check out the video interview.
Phil is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth.
Phil received his Ph.D. in Biochemistry and Molecular Biology at Georgetown University Medical Center followed by an IRTA fellowship at the National Cancer Institute in Maryland, and at the Hollings Cancer Center in Charleston, SC. Phil was an instructor for Johns Hopkins University Advanced Academic Programs teaching Biotechnology Marketing in the Masters of Biotechnology / MBA program, and has held leadership positions in a number of life sciences companies including Life Technologies, Becton Dickinson, and Lonza. Phil is a Board Member of CCRM in Toronto Canada and a Board Member of the ARM Foundation.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
